Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,350 stories, page 390 of 673

Advanced search

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT06207799: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT06169397: An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT06068257: Tumor-Derived FGF19

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT06067399: Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT06021600: A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT05724121: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT05665777: Chinese Medicine for Treating Chronic Pharyngolaryngitis

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT05503225: Colchicine Use in Intracranial Atherosclerotic Disease

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT05344469: A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT05154487: A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT04994132: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT04935606: mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT03606837: 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT03363373: Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02981628: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02720458: Self Help Program for Hypnotics Withdrawal in Insomniac Patients

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02654119: Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT02152982: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study type: INTERVENTIONAL. Phase: PHASE2, PHASE3.

ClinicalTrials.govOriginal source

🇺🇸Jul 30Researchclinicaltrials.govTier 1 · Trial registry

NCT00070499: Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Early surgery for acute eye infection offers hope to patients

Clarity NewsOriginal source

🇺🇸Jul 30Industrytechcyte.comTier 1 · Company source

Techcyte Announces OptiPath’s Adoption of the Techcyte Fusion® Platform for Cytology and Histology

TechcyteOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility

Applied Clinical Trials OnlineOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Elix and University of Vienna Aim to Advance Drug Discovery Using AI

Genetic Engineering and Biotechnology NewsOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply

Partnership for Safe MedicinesOriginal source

🌍Jul 30discoverynews.google.comTier 2 · Trade media

FDA expert panel recommends against approval of Capricor’s Duchenne drug

statnews.comOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

DOD Biotech Public Co., Ltd. Revenue Breakdown – SET:DOD

TradingViewOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

9th Circ. Revives Biotech Worker's Pension Plan Suit

Law360Original source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Trip Advisor: FDA Publishes Guidance on Psychedelic Drug Trials

The National Law ReviewOriginal source

🇪🇸Jul 30Researchcnic.esTier 2 · Direct publisher

Ben Lehner: "Una buena gobernanza es tan importante como una buena ciencia"

CNIC Spain CardiovascularOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline

neurologylive.comOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG

Yahoo FinanceOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

What the FDA’s Peptide Vote Actually Means

mensfitness.comOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO

Bloomberg.comOriginal source

🌍Jul 30discoverynews.google.comTier 2 · Trade media

MapLight CEO on what investors missed in the biotech’s schizophrenia data

biopharmadive.comOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

259 pro-abortion lawmakers urge court to keep abortion pill access easy

liveaction.orgOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

Streetwise ReportsOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Scancell, Neuphoria Agree to All-Share Merger

Streetwise ReportsOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

What to Know About the 6 Peptides Backed by an FDA Advisory Panel

Verywell HealthOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary

TradingViewOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Vivozon expands Onapra into chronic pain, targets US phase 3 and tech transfer - CHOSUNBIZ

ChosunbizOriginal source

🌍Jul 30discoverynews.google.comTier 2 · Trade media

Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx

STATOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

The Manila TimesOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

What to know about pharmaceutical tariffs

Healthcare BrewOriginal source

🇺🇸Jul 30Researchatlasventure.comTier 2 · Direct publisher

Less than year after launch, Caldera lines up $278M financing and Nasdaq debut

Atlas VentureOriginal source

🌍Jul 30Industrycormedix.comTier 1 · Company source

CORMEDIX THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 13, 2026

CorMedixOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TradingViewOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

FDA Approves First-Ever Freeze-Dried Plasma Product

The Well NewsOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Arkansas suspends enforcement of law limiting pharmaceutical distribution

The Arkansas Democrat-GazetteOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD

Genetic Engineering and Biotechnology NewsOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

Yahoo FinanceOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

PR NewswireOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

FDA Approves Viatris's Gwyn Lo | PharmExec

pharmexec.comOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

New Singham in town? Maharashtra FDA chief defends crackdown on Mumbai eateries

India TodayOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Opinion | The U.S. could become dependent on China for life-saving drugs

The Washington PostOriginal source

🇧🇷Jul 30Regulatoryinterfarma.org.brTier 1 · Regulatory source

Interfarma integra o CNCP e amplia contribuição ao combate à pirataria e defesa da inovação

Interfarma BrazilOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Pancreatic Cancer Drug Doubled Survival in Phase 3 Trial. Who Qualifies for Expanded Access?

Medical DailyOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

UConn School of Pharmacy and Pharmaceutical Sciences Professor Xiuling Lu Receives Director Promotion

UConn TodayOriginal source

🌍Jul 30discoverynews.google.comTier 3 · Aggregated media

Six Months In: A 2026 Progress Check on Pharma Dealmaking, Access and Commercialization

Pharmaceutical CommerceOriginal source

Pharmaceutical industry news

NCT06207799: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06169397: An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT06068257: Tumor-Derived FGF19

NCT06067399: Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

NCT06021600: A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

NCT05724121: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05665777: Chinese Medicine for Treating Chronic Pharyngolaryngitis

NCT05503225: Colchicine Use in Intracranial Atherosclerotic Disease

NCT05344469: A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

NCT05154487: A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

NCT04994132: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

NCT04935606: mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care

NCT03606837: 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging

NCT03363373: Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT02981628: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02720458: Self Help Program for Hypnotics Withdrawal in Insomniac Patients

NCT02654119: Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02152982: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00070499: Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Early surgery for acute eye infection offers hope to patients

Techcyte Announces OptiPath’s Adoption of the Techcyte Fusion® Platform for Cytology and Histology

FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility

Elix and University of Vienna Aim to Advance Drug Discovery Using AI

PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply

FDA expert panel recommends against approval of Capricor’s Duchenne drug

DOD Biotech Public Co., Ltd. Revenue Breakdown – SET:DOD

9th Circ. Revives Biotech Worker's Pension Plan Suit

Trip Advisor: FDA Publishes Guidance on Psychedelic Drug Trials

Ben Lehner: &quot;Una buena gobernanza es tan importante como una buena ciencia&quot;

Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline

Dr. Sven K. Weber Succeeds Adriaan Moelker as CEO of BRAIN Biotech AG

What the FDA’s Peptide Vote Actually Means

Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO

MapLight CEO on what investors missed in the biotech’s schizophrenia data

259 pro-abortion lawmakers urge court to keep abortion pill access easy

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

Scancell, Neuphoria Agree to All-Share Merger

What to Know About the 6 Peptides Backed by an FDA Advisory Panel

PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary

Vivozon expands Onapra into chronic pain, targets US phase 3 and tech transfer - CHOSUNBIZ

Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

What to know about pharmaceutical tariffs

Less than year after launch, Caldera lines up $278M financing and Nasdaq debut

CORMEDIX THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 13, 2026

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

FDA Approves First-Ever Freeze-Dried Plasma Product

Arkansas suspends enforcement of law limiting pharmaceutical distribution

Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

FDA Approves Viatris's Gwyn Lo | PharmExec

New Singham in town? Maharashtra FDA chief defends crackdown on Mumbai eateries

Opinion | The U.S. could become dependent on China for life-saving drugs

Interfarma integra o CNCP e amplia contribuição ao combate à pirataria e defesa da inovação

Pancreatic Cancer Drug Doubled Survival in Phase 3 Trial. Who Qualifies for Expanded Access?

UConn School of Pharmacy and Pharmaceutical Sciences Professor Xiuling Lu Receives Director Promotion

Six Months In: A 2026 Progress Check on Pharma Dealmaking, Access and Commercialization

Ben Lehner: "Una buena gobernanza es tan importante como una buena ciencia"